Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRK1 | P41145 | 6/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.43 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.39 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.39 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.39 |
| ▸ | UBE2M | P61081 | 3/20 | 0.38 |
| ▸ | DCUN1D1 | Q96GG9 | 3/20 | 0.38 |
| ▸ | BDKRB1 | P46663 | 2/20 | 0.37 |
| ▸ | CCR2 | P41597 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9101607 | 1.00 | OPRK1 (0.43) | OPRK1CYP2D6HRH3OPRM1OPRD1 | |
| SCHEMBL9104308 | 0.86 | TACR2 (0.41) | OPRK1CYP2D6 | |
| SCHEMBL31478933 | 0.86 | TACR2 (0.41) | OPRK1CYP2D6 | |
| SCHEMBL9104300 | 0.86 | TACR2 (0.41) | OPRK1CYP2D6 | |
| SCHEMBL9104502 | 0.82 | HRH3 (0.44) | OPRK1CYP2D6HRH3OPRM1OPRD1 | |
| SCHEMBL9104486 | 0.82 | HRH3 (0.44) | OPRK1CYP2D6HRH3OPRM1OPRD1 | |
| SCHEMBL9106114 | 0.80 | SMO (0.41) | OPRK1CYP2D6OPRM1OPRD1 | |
| SCHEMBL9106105 | 0.80 | SMO (0.41) | OPRK1CYP2D6OPRM1OPRD1 | |
| SCHEMBL9102911 | 0.78 | HRH3 (0.44) | OPRK1CYP2D6HRH3OPRM1OPRD1 | |
| SCHEMBL9101346 | 0.78 | HRH3 (0.44) | OPRK1CYP2D6HRH3OPRM1OPRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025082731-A1 | INTRANASAL FORMULATIONS FOR TREATING OBSTRUCTIVE SLEEP APNEA | MOSANNA THERAPEUTICS AG (CH) | 2025-04-24 | — | — | WO | disclosed |